Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics

Next Previous
X
Search
Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics

Alternative Names: ICTCAR003

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovative Cellular Therapeutics
  • Developer Innovative Cellular Therapeutics; Zhejiang University
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B-cell lymphoma; Non-Hodgkin's lymphoma
  • No development reported Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia; Lymphoid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for preclinical development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in China (Parenteral)
  • 28 Jan 2021 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
  • 28 Jan 2021 No recent reports of development identified for phase-I development in Follicular lymphoma(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top